Influenza B virus hemagglutinin
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2020
- First approval year
- 2020
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Influenza B virus hemagglutinin
- influenza b virus hemagglutinin component of supemtek
- Influenza b virus hemagglutinin component of supemtek
- influenza b virus hemagglutinin
- Influenza b virus hemagglutinin
- ChEMBL ID
- CHEMBL6068388
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
Mechanisms of action
- Mechanism
- Hemagglutinin vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Hemagglutinin
- Protein identifier
- P03460
Open Targets mechanisms
- Mechanism
- Hemagglutinin vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Hemagglutinin
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Influenza, Human
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
Open Targets indications
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 4
- Dose
- 0.5mL
- Route
- Intramuscular
- How often
- Single dose
Conditions of use
- Inspect visually for particulate matter and discoloration prior to administration
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
- Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients